CD274 and neoplasm: In a phase II pan tumor trial, an oral dual blocker anti-VISTA and PD-L1 agent (CA-170) showed a clinical benefit of 75% and a median PFS of 19.5 weeks among eight previously treated nonsquamous NSCLC patients (71).